JP2009515831A5 - - Google Patents

Download PDF

Info

Publication number
JP2009515831A5
JP2009515831A5 JP2008537233A JP2008537233A JP2009515831A5 JP 2009515831 A5 JP2009515831 A5 JP 2009515831A5 JP 2008537233 A JP2008537233 A JP 2008537233A JP 2008537233 A JP2008537233 A JP 2008537233A JP 2009515831 A5 JP2009515831 A5 JP 2009515831A5
Authority
JP
Japan
Prior art keywords
antigen
antigens
immunogenic composition
combination
pestis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008537233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009515831A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2006/003843 external-priority patent/WO2007049155A2/en
Publication of JP2009515831A publication Critical patent/JP2009515831A/ja
Publication of JP2009515831A5 publication Critical patent/JP2009515831A5/ja
Pending legal-status Critical Current

Links

JP2008537233A 2005-10-25 2006-10-25 ペスト菌(Yersiniapestis)抗原を含む組成物 Pending JP2009515831A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73018205P 2005-10-25 2005-10-25
US81783806P 2006-06-30 2006-06-30
PCT/IB2006/003843 WO2007049155A2 (en) 2005-10-25 2006-10-25 Compositions comprising yersinia pestis antigens

Publications (2)

Publication Number Publication Date
JP2009515831A JP2009515831A (ja) 2009-04-16
JP2009515831A5 true JP2009515831A5 (enExample) 2010-11-11

Family

ID=37968196

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008537233A Pending JP2009515831A (ja) 2005-10-25 2006-10-25 ペスト菌(Yersiniapestis)抗原を含む組成物

Country Status (6)

Country Link
US (1) US7776336B2 (enExample)
EP (1) EP1954306A2 (enExample)
JP (1) JP2009515831A (enExample)
AU (1) AU2006307602A1 (enExample)
CA (1) CA2627302A1 (enExample)
WO (1) WO2007049155A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
GB0525213D0 (en) * 2005-12-12 2006-01-18 Secr Defence Vaccine
US10174100B1 (en) * 2006-11-06 2019-01-08 Microvax, Llc Multivalent DNA composition for Yersinia pestis
GB0717187D0 (en) * 2007-09-04 2007-10-17 Novartis Ag Compositions comprising yersinia pestis antigens
WO2010117455A2 (en) * 2009-04-08 2010-10-14 U.S. Army Medical Research Institute Of Infectious Diseases Human monoclonal antibodies protective against bubonic plaque
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
JP2013512256A (ja) * 2009-11-24 2013-04-11 インビラジェン, インコーポレイテッド 腸内細菌関連ペプチドの発現に関する組成物、方法、および使用
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のrnaを用いた大型哺乳動物の免疫化
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
DK2590676T3 (en) 2010-07-06 2016-10-24 Glaxosmithkline Biologicals Sa Virionlignende feed particles to self-replicating RNA molecules
RS54489B1 (sr) 2010-07-06 2016-06-30 Glaxosmithkline Biologicals Sa Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk
BR112013004865A2 (pt) 2010-08-31 2016-06-07 Novartis Ag lípidos adequados para entrega lipossomal de codificadores de proteínas rna
SMT202200311T1 (it) 2010-08-31 2022-09-14 Glaxosmithkline Biologicals Sa Liposomi pegilati per somministrare rna codificante un immunogene
EP3520813B1 (en) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
WO2012129483A1 (en) 2011-03-24 2012-09-27 Novartis Ag Adjuvant nanoemulsions with phospholipids
US20140141070A1 (en) 2011-07-06 2014-05-22 Andrew Geall Liposomes having useful n:p ratio for delivery of rna molecules
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US20140255472A1 (en) 2011-08-31 2014-09-11 Andrew Geall Pegylated liposomes for delivery of immunogen-encoding rna
EP4056198A3 (en) 2012-09-18 2022-12-07 GlaxoSmithKline Biologicals SA Outer membrane vesicles
KR102255108B1 (ko) 2013-03-08 2021-05-24 노파르티스 아게 활성제의 전달을 위한 지질 및 지질 조성물
EP3623361B1 (en) 2013-12-19 2021-08-18 Novartis AG Lipids and lipid compositions for the delivery of active agents
ES2908827T3 (es) 2013-12-19 2022-05-04 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
WO2016010840A1 (en) 2014-07-16 2016-01-21 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
ES2969956T3 (es) 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
EP4229208A4 (en) 2020-10-14 2024-10-30 George Mason Research Foundation, Inc. METHOD FOR THE PRODUCTION OF LIPID DNANOPARTICLES AND COMPOSITIONS THEREOF
CN112609013A (zh) * 2021-01-12 2021-04-06 深圳市赛格诺生物科技有限公司 一种用于检测鼠疫耶尔森菌的荧光pcr试剂及方法
WO2023021421A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
US20240350410A1 (en) 2021-08-16 2024-10-24 Glaxosmithkline Biologicals Sa Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation
GB202311382D0 (en) 2023-07-25 2023-09-06 Glaxosmithkline Biologicals Sa Lyophilised compostion

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525213D0 (en) 2005-12-12 2006-01-18 Secr Defence Vaccine

Similar Documents

Publication Publication Date Title
JP2009515831A5 (enExample)
JP2012501959A5 (enExample)
JP2006526414A5 (enExample)
DE60329106D1 (de) Ghrelin-träger-konjugate
JP2010162023A5 (enExample)
JP2008529558A5 (enExample)
WO2006045796A3 (en) Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof
WO2006063974A3 (en) Il-15 antigen arrays and uses thereof
JP2017507117A5 (enExample)
PL369863A1 (en) Antigen arrays for treatment of allergic eosinophilic diseases
JP2009504654A5 (enExample)
JP2010532656A5 (enExample)
AU2003246373A8 (en) Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions
JP2013505017A5 (enExample)
WO2003039225A3 (en) Antigen arrays comprising rankl for treatment of bone disease
JP2011517938A5 (enExample)
JP2015529677A5 (enExample)
JP2010538619A5 (enExample)
JP2002534481A5 (enExample)
JP2016528176A5 (enExample)
EP1762620A3 (en) Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
Nuzzaci et al. In vitro stability of Cucumber mosaic virus nanoparticles carrying a Hepatitis C virus-derived epitope under simulated gastrointestinal conditions and in vivo efficacy of an edible vaccine
JP2006523185A5 (enExample)
WO2008027560A3 (en) Holin-enhanced vaccines and reagents, and methods of use thereof
JP2005524719A5 (enExample)